PER® Chemotherapy Foundation Symposium (CFS) | Conference

Dr. Levy on the Future of Atezolizumab in NSCLC

November 11th 2022

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma

November 11th 2022

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

Dr. Perl on Genetic Testing and Targeted Therapies in AML

November 10th 2022

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

Every Patient With Metastatic Melanoma “Deserves a Shot at Nivolumab/Ipilimumab,” Weber Says

November 10th 2022

The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.

Rugo Highlights Key Priorities for the Future of Breast Cancer Research

November 10th 2022

Research in breast cancer has led to remarkable progress in the understanding and management of the disease, but the oncology community can always do more to optimize treatment outcomes for patients.

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10th 2022

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment

November 10th 2022

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

Breast Cancer Advances in 2022 Shape CFS Agenda

November 10th 2022

Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions.

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

November 9th 2022

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Frontline Setting Boasts Multiple Treatment Options for Patients With ALL

November 9th 2022

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

Targeted Therapies Make Major Strides in mCRC Management

November 7th 2021

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

November 5th 2021

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer.

Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC

November 5th 2021

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Dr. Davidson on Leveraging Imaging Technologies to Inform Clinical Decisions in Breast Cancer

November 4th 2021

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Personalized Medicine Could Be the Key to Bridging Health Disparities in Cancer Care

November 4th 2021

Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.

Bispecific Monoclonal Antibodies Lead Immune-Directed Therapies into the Future

November 4th 2021

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.